Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs

被引：0
|
作者：
Schultz, RM [1 ]
Chen, VJ [1 ]
Bewley, JR [1 ]
Roberts, EF [1 ]
Shih, C [1 ]
Dempsey, JA [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA
来源：
SEMINARS IN ONCOLOGY | 1999年 / 26卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 73
页数：6
相关论文
共 50 条
  • [31] Quality of life assessments of patients with pancreatic cancer receiving MTA (LY231514, a multi-targeted antifolate)
    Liepa, AM
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Schulman, L
    Burris, A
    Thornton, D
    Loehrer, PJ
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : OP19 - OP19
  • [32] Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs
    Takemura, Y
    Kobayashi, H
    Miyachi, H
    Gibson, W
    Kimbell, R
    Jackman, AL
    JAPANESE JOURNAL OF CANCER RESEARCH, 1996, 87 (07): : 773 - 780
  • [33] A multicentre phase II trial of the multi-targeted antifolate MTA (LY231514) in chemonaive patients with metastatic renal cell carcinoma
    Sauter, T
    Boucsein, G
    Thoedtmann, R
    Miller, K
    Ohnmacht, U
    Blatter, J
    Hanauske, AR
    ANNALS OF ONCOLOGY, 1998, 9 : 61 - 61
  • [34] Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: Results of a phase II trial
    Paz-Ares, L
    Tabemero, J
    Moyano, A
    Rifa, J
    Alonso, S
    Marcuello, E
    Gonzalez, A
    Castellano, D
    Hemandez, S
    Cortes-Funes, H
    ANNALS OF ONCOLOGY, 1998, 9 : 61 - 61
  • [35] Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder:: Results of a phase II trial.
    Paz-Ares, J
    Tabernero, A
    Moyano, A
    Rifa, J
    Alonso, S
    Marcuello, E
    Gonzalez, A
    Castellano, D
    Cortés-Funes, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S81 - S81
  • [36] Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
    Rusthoven, JJ
    Eisenhauer, E
    Butts, C
    Gregg, R
    Dancey, J
    Fisher, B
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1194 - 1199
  • [37] Effects of MTA (multi-targeted antifolate, LY231514) on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells
    Chen, VJ
    Bewley, JR
    Andis, SL
    Schultz, RM
    Shih, C
    Mendelsohn, LG
    Seitz, DE
    Tonkinson, JL
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 803 - 803
  • [38] A phase I study of MTA (multi-targeted antifolate, LY231514) plus cisplatin (CIS) in patients with advanced solid tumours
    Thoedtmann, R
    Kemmerich, M
    Depenbrock, H
    Blatter, J
    Ohnmacht, U
    Rastetter, J
    Hanauske, AR
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1116 - 1116
  • [39] Synergistic interaction of the multitargeted antifol (MTA, LY 231514) with melphalan in vitro in human tumor cell lines.
    Budman, DR
    Calabro, A
    Kreis, W
    CLINICAL CANCER RESEARCH, 1999, 5 : 3861S - 3861S
  • [40] A phase I dose escalation study of the multitargeted antifolate, LY231514 (MTA) in combination with 5-fluorouracil (5-FU): Dependence of toxicity on schedule of 5-FU administration
    Johnson, T
    Schwartz, G
    McCune, D
    Stephenson, J
    Aylesworth, C
    Hammond, L
    Monroe, P
    Thornton, D
    Von Hoff, D
    Rowinsky, E
    ANNALS OF ONCOLOGY, 1998, 9 : 160 - 160
12345